These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 27902470)
1. Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Zhang T; Li Q; Chen S; Luo Y; Fan Y; Xu B Oncotarget; 2017 May; 8(22):36750-36760. PubMed ID: 27902470 [TBL] [Abstract][Full Text] [Related]
2. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Tevaarwerk AJ; Kolesar JM Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044 [TBL] [Abstract][Full Text] [Related]
3. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 Moulder SL; Borges VF; Baetz T; Mcspadden T; Fernetich G; Murthy RK; Chavira R; Guthrie K; Barrett E; Chia SK Clin Cancer Res; 2017 Jul; 23(14):3529-3536. PubMed ID: 28053022 [No Abstract] [Full Text] [Related]
4. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781 [TBL] [Abstract][Full Text] [Related]
5. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146 [TBL] [Abstract][Full Text] [Related]
6. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417 [TBL] [Abstract][Full Text] [Related]
7. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672 [TBL] [Abstract][Full Text] [Related]
8. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484 [TBL] [Abstract][Full Text] [Related]
9. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. Rocca A; Cecconetto L; Passardi A; Melegari E; Andreis D; Monti M; Maltoni R; Sarti S; Pietri E; Schirone A; Fabbri F; Donati C; Nanni O; Fedeli A; Faedi M; Amadori D Cancer Chemother Pharmacol; 2017 May; 79(5):863-871. PubMed ID: 28341957 [TBL] [Abstract][Full Text] [Related]
10. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer. Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386 [TBL] [Abstract][Full Text] [Related]
11. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256 [TBL] [Abstract][Full Text] [Related]
14. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900 [TBL] [Abstract][Full Text] [Related]
15. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE Eur J Cancer; 2016 Mar; 56():85-92. PubMed ID: 26829011 [TBL] [Abstract][Full Text] [Related]
16. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Medina PJ; Goodin S Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986 [TBL] [Abstract][Full Text] [Related]
17. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Johnston SR; Leary A Drugs Today (Barc); 2006 Jul; 42(7):441-53. PubMed ID: 16894399 [TBL] [Abstract][Full Text] [Related]
18. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923 [TBL] [Abstract][Full Text] [Related]
20. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]